Do Analysts Agree on Aphria Inc (APHA) Stock's Target Price?

Monday, March 23, 2020 9:48 AM | InvestorsObserver Analysts

Wall Street is positive on Aphria Inc (APHA). On average, analysts give Aphria Inc a Strong Buy rating. The average price target is $7.171, which means analysts expect the stock to add by 175.81% over the next twelve months.

That average ranking earns Aphria Inc an Analyst Rating of 62, which is better than 62% of stocks based on data compiled by InvestorsObserver.

Overall Score - 4.4
Wall Street analysts are rating APHA a Strong Buy today. Find out what this means to you and get the rest of the rankings on APHA!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.

InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Aphria Inc Stock Today?

Aphria Inc (APHA) stock is trading at $2.60 as of 9:47 AM on Monday, Mar 23, a rise of $0.09, or 3.59% from the previous closing price of $2.51. The stock has traded between $2.47 and $2.74 so far today. Volume today is less active than usual. So far 300,832 shares have traded compared to average volume of 5,387,936 shares.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Is Global Cord Blood Corp (CO) Stock a Great Value?

Denali Therapeutics Inc (DNLI) Stock Climbs 10.58% This Week; Should You Buy?

Should Replimune Group Inc (REPL) Stock be in Your Portfolio?

Should You Buy AcelRx Pharmaceuticals Inc (ACRX) Stock?

Sector Update: Health Care Stocks Slipping in Late Trade

Related Companies